NCCS Joins Patient Advocate Colleagues in Commenting on FDA Document on Expedited Programs for Serious Conditions
NCCS joined its patient advocate colleagues in the Cancer Leadership Council in comments on a Food and Drug Administration (FDA) document that provides guidance about the use of certain “expedited programs” that may be employed in the review of therapies for serious conditions. The FDA has updated the guidance regarding fast track and priority review […]